Misonix — Merger or Acquisition (May 2019)
13 slides from Misonix's merger presentation, May 2, 2019
Slide 1: Misonix – Vision for the Future
Misonix –Vision for the Future
Slide 2: Forward Looking Statements
Forward Looking Statements This communication contains forward-looking statements, which address a variety of subjects including, for example, the expected timetable for closing of the transaction between Misonix and Solsys, the allocation of the merger consideration and the anticipated growth rate
Slide 3: Participants in the Solicitation; Non-Solicitation
Participants in the Solicitation Misonix, Solsys and certain of their directors, executive officers and employees may be deemed participants in the solicitation of proxies from Misonix stockholders in connection with the proposed transaction. Information regarding the persons who may be deemed to be
Slide 4: Today's Announcement
Today’s Announcement + Misonix, Inc. Enters into Definitive Agreement to Acquire Regenerative Medical Company Solsys Medical for Approximately $97M Broadens Wound Care Advances go-to-market Enhances Misonix’s financial platform with cellular skin strategy and expected to drive profile by adding sign
Slide 5: Transaction Rationale
Transaction Rationale 1 Creates a platform with estimated pro forma calendar 2018 product revenue of $60.6M and supports Misonix’s pro forma top-line growth of 20%+ 2 Expands Misonix’s addressable market from $1.1B to over $1.78B 3 Broadens Misonix’s commercial infrastructure to over 136 dedicated s
Slide 6: Solsys Medical at a Glance
Solsys Medical at a Glance Business Summary Company Highlights • Privately-held, regenerative wound care company • Cellular skin substitute product with large addressable market • Markets TheraSkin® human skin allograft • Specialized Wound Care sales team with experience • 81 Dedicated Sales Resourc
Slide 7: Misonix at a Glance
Misonix at a Glance Business Summary Company Highlights • Public company, Ultrasonic surgical platform for • Ultrasonic surgical bone cutting and shaving for spine precision tissue removal surgery • Address large chronic global healthcare issues • Ultrasonic surgical soft tissue removal for brain tu
Slide 8: TheraSkin at a Glance
TheraSkin at a Glance Cost-effective solution with A biologically active cryopreserved, favorable coverage and human skin allograft for chronic wounds reimbursement Indicated for chronic wounds head-to-toe, including more At-ready supply of human growth severe wounds with exposed factors, cytokines
Slide 9: Redefining the Standard of Care
Redefining the Standard of Care • Unsolved Problem - huge unmet need to • Addresses objective of securing patient improve debridement practice for Wound earlier in wound healing cycle Care • Initial sales expansion opportunity in OR • Only ~20% of Wound Care physicians via dedicated Wound Care sales
Slide 10: Misonix's Existing Commercial Infrastructure
Misonix’s Existing Commercial Infrastructure 55 Dedicated Sales Resources … BoneScalpel SonaStar SonicOne Target Target Target Spine Neuro / General Wound Care Specialty Specialty Specialty Target Target Target Inpatient Inpatient Inpatient Channel Channel Channel U.S. TAM ~$600M U.S. TAM ~$263M U.S
Slide 11: Vision for the New Misonix
Vision for the New Misonix 136 Dedicated Sales Resources… 55 Dedicated 81 Dedicated Sales + Sales Resources Resources Surgical Franchise Wound Care Franchise Wound Care ( Podiatry, Plastic Target Specialty Surgical (Spine, Neuro, General) Target Specialty Surgery. Foot and Ankle, Vascular) Target Ch
Slide 12: Transaction Summary
Transaction Summary Transaction Details Transaction • All-stock transaction valuing Solsys Medical at an equity value of ~$97M Terms • Misonix will issue approximately 5.7M shares upon the closing of the transaction Ownership • Pro forma combined company ownership: 64.0% current Misonix shareholders
Slide 13: Questions?
mISONIM&., BETTER MATTERS™ Questions?